AVTX - CIK 0001534120
Avalo Therapeutics, Inc. (AVTX) reported revenue of $59.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $59.00K | -86.6% |
| FY 2024 | $441.00K | -77.1% |
| FY 2023 | $1.92M | -89.3% |
| FY 2022 | $18.05M | +234.4% |
| FY 2021 | $5.40M | -19.4% |
| FY 2020 | $6.70M | -0.8% |
| FY 2019 | $6.75M | -4.0% |
| FY 2018 | $7.03M | -74.7% |
| FY 2017 |
Avalo Therapeutics, Inc. (AVTX) reported revenue of $59.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, Avalo Therapeutics, Inc.'s revenue grew from $0.00 to $59.00K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $27.81M |
| +2312.3% |
| FY 2016 | $1.15M | - |
| FY 2015 | $0.00 | - |